Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clovis Oncology and Evergreen Theragnostics have initiated a development, manufacturing, and services agreement for actinium-225-labeled-FAP-2286 (225Ac-FAP-2286).
Clovis Oncology and Evergreen will develop radiolabelling chemistry and analytical methods for future pre-clinical and clinical studies. Credit: National Cancer Institute on Unsplash.
Subscribe to our email newsletter
Under the deal, the companies will develop radiolabelling chemistry and analytical methods which will be utilised in future pre-clinical and clinical studies.
Actinium-225 (225Ac) is an alpha particle-emitting radionuclide which is suitable for targeted radiotherapy applications depending on its half-life of about ten days.
It has the ability to provide a meaningful radiation dose to target tumours while enabling the central manufacturing and distribution of 225Ac-FAP-2286.
Clovis Oncology president and CEO Patrick Mahaffy said: “This agreement with Evergreen Theragnostics represents an important step forward for Clovis in our efforts to optimise our clinical development programme for FAP-2286.
“We are enthusiastic about exploring the potential of FAP-2286 labelled with actinium-225 in our targeted radiopharmaceuticals programme.
“Actinium-225 represents an emerging radionuclide that is generating significant interest for its potential for therapeutic use.”
An investigational clinical candidate, FAP-2286 is the first peptide-targeted radionuclide therapy (PTRT) and imaging agent which targets fibroblast activation protein (FAP).
It comprises two functional elements that include a targeting peptide which binds to FAP as well as a site that can be used to attach radioactive isotopes for use in imaging and therapy.
The investigational therapy agent is connected to lutetium-177 labeled FAP-2286 (177Lu-FAP-2286) in the Phase I/II LuMIERE study (NCT04939610).
As per the terms of the deal, Evergreen will be responsible for the development of 225Ac-FAP-2286 at its facility located in Springfield, New Jersey.
Evergreen Theragnostics CEO James Cook said: “Actinium-based radiotherapies offer the potential to play an important role in the fight against cancer.
“We seek to provide a robust and efficient radiopharmaceutical manufacture, testing, and supply process for our partners from early-stage development through commercialisation.”
